ArticleF&S reports2022
Fertility preservation in transgender men without discontinuation of testosterone.
Article in F&S reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Oocyte cryopreservation for fertility preservation in transgender and gender diverse individuals: a SWOT analysis.Journal of assisted reproduction and genetics · 2025Review
- Fertility treatments in transgender individuals: trends, clinical outcomes, and impact of testosterone on ovarian stimulation.Journal of assisted reproduction and genetics · 2025Observational
- Turner Syndrome and Gender Incongruence: Considerations for Gender Affirming Hormonal Therapy.Case reports in endocrinology · 2025Article
- Clinical and ethical perspectives of ovarian stimulation and oocyte cryopreservation in adolescents: 6 years experience from a tertiary centre.Human reproduction open · 2025Article
- REPRODUCTIVE HEALTH IN TRANS AND GENDER-DIVERSE PATIENTS: Gonadal tissue cryopreservation in transgender and gender-diverse people.Reproduction (Cambridge, England) · 2024Review
- Thoughts and opinions about fertility preservation and family building from the transgender community-an interview-based approach.AJOG global reports · 2024Article
- Oocyte cryopreservation and reciprocal in vitro fertilization in a transgender man on long term testosterone gender-affirming hormone therapy: a case report.F&S reports · 2024Article
- A Gender-Affirming Approach to Fertility Care for Transgender and Gender-Diverse Patients.O&G open · 2024Article
- Clinical management of transgender and non-binary patients in the fertility preservation service: Current evidence.International journal of transgender health · 2024Review
- Fertility treatment outcomes in transgender men with a history of testosterone therapy.F&S reports · 2023Article
- In vitro fertilization outcomes in a mouse model of gender-affirming hormone therapy in transmasculine youth.F&S science · 2023Article
- Reproductive capacity after gender-affirming testosterone therapy.Human reproduction (Oxford, England) · 2023Article
- Impaired in vitro fertilization outcomes following testosterone treatment improve with washout in a mouse model of gender-affirming hormone treatment.American journal of obstetrics and gynecology · 2023Article
- Endocrine Health and Health Care Disparities in the Pediatric and Sexual and Gender Minority Populations: An Endocrine Society Scientific Statement.The Journal of clinical endocrinology and metabolism · 2023Article
- Desire for genetically related children among transgender and gender-diverse patients seeking gender-affirming hormones.F&S reports · 2023Article
- "Lights and Shades" of Fertility Preservation in Transgender Men Patients: A Clinical and Pathological Review.Life (Basel, Switzerland) · 2023Review
- Oocyte Cryopreservation for Medical and Planned Indications: A Practical Guide and Overview.Journal of clinical medicine · 2023Review
- Fertility counseling guide for transgender and gender diverse people.International journal of transgender health · 2023Article
- Fertility Preservation and Reproductive Potential in Transgender and Gender Fluid Population.Biomedicines · 2022Review
- First Childbirth after Fertility Preservation and Gender Reassigning Surgery from Indian Transgender Community.Journal of human reproductive sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report two cases of fertility preservation in two transgender men without an extended period of higher dose testosterone cessation. Design: Chart abstraction was completed for two cases of oocyte preservation in transgender men without stopping testosterone gender-affirming therapy before controlled ovarian stimulation (COS). Setting: A university-affiliated fertility clinic in San Francisco, California. Patients: Two 27-year-old transgender men on higher dose testosterone undergoing oocyte cryopreservation. Interventions: Not applicable. Main Outcome Measures: Both patients had been on 6 and 20 months of testosterone therapy, respectively, and continued throughout COS. A random start antagonist plus letrozole protocol was used for the patient in case 1, with a leuprolide acetate trigger. A luteal start antagonist protocol was applied to the patient in case 2 with a leuprolide acetate trigger. Results: In case 1, a total of 35 oocytes were retrieved, with a total of 23 metaphase II (MII) oocytes cryopreserved. An additional 7 MII oocytes were obtained after in vitro maturation for a total of 30 MII oocytes that were vitrified. In case 2, 14 oocytes were retrieved, and 9 mature oocytes (MII) were vitrified. Conclusions: Transgender men have historically been advised to discontinue testosterone before COS, a process that may be distressing for many individuals. This is the first published case report demonstrating the proof of concept of COS without cessation of high-dose testosterone therapy in two transgender men. Future studies with larger sample sizes should be performed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.